Open AccessCombination of survivin siRNA with neoadjuvant chemotherapy enhances apoptosis and reverses drug resistance in breast cancer MCF-7 cells
Author(s) -
Honglin Dong,
Luyu Yao,
Weilin Bi,
Fusheng Wang,
Wei Song,
Yonggang Lv
Publication year - 2015
Publication title -
journal of cancer research and therapeutics/journal of cancer research and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.475
H-Index - 39
eISSN - 0973-1482
pISSN - 1998-4138
DOI - 10.4103/0973-1482.147764
Subject(s) - survivin , epirubicin , cancer research , transfection , chemotherapy , paclitaxel , apoptosis , breast cancer , small interfering rna , medicine , mcf 7 , cancer , chemistry , biology , cell culture , biochemistry , human breast , genetics
Chemotherapeutic resistance is a main problem in clinical breast cancer therapy. The purpose of our study is to investigate whether the combination of neoadjuvant chemotherapy and survivin siRNA treatment could enhance the therapeutic effect of neoadjuvant chemotherapy using paclitaxel or epirubicin.